Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

by Gridelli, Cesare , Han, Ji-Youn , Haney, Jeff , Tiseo, Marcello , Camidge, D. Ross , Chang, Gee-Chen , Yang, James Chih-Hsin , Morabito, Alessandro , Lee, Ki Hyeong , Kim, Hye Ryun , Bearz, Alessandra , Kim, Dong-Wan , Kerstein, David , Garcia Campelo, Rosario , Ghosh, Sharmistha , Spira, Alexander , Ahn, Myung-Ju , Lee, Jong-Seok , Griesinger, Frank , Felip, Enriqueta , Califano, Raffaele , Gupta, Neeraj , Hochmair, Maximilian J , Gettinger, Scott N , Delmonte, Angelo , Li, Jacky Yu-Chung , Popat, Sanjay

in Adult / Aged / Aged, 80 and over / Anaplastic Lymphoma Kinase - analysis / Anaplastic Lymphoma Kinase - antagonists & inhibitors / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Brain Neoplasms - secondary / Cancer therapies / Carcinoma, Non-Small-Cell Lung - chemistry / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - secondary / Chemotherapy / Crizotinib - adverse effects / Crizotinib - therapeutic use / Drug dosages / Enzyme inhibitors / Female / Humans / Inhibitor drugs / Kaplan-Meier Estimate / Lung cancer / Lung Neoplasms - chemistry / Lung Neoplasms - drug therapy / Lung Neoplasms - pathology / Lymphoma / Male / Medical imaging / Metastasis / Middle Aged / Mutation / NMR / Non-small cell lung carcinoma / Nuclear magnetic resonance / Organophosphorus Compounds - adverse effects / Organophosphorus Compounds - therapeutic use / Pharmaceuticals / Progression-Free Survival / Protein-tyrosine kinase / Pyrimidines - adverse effects / Pyrimidines - therapeutic use / Radiation therapy / Statistical analysis / Targeted cancer therapy / Technical communication

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

2018

Confirm

Do you wish to request the book?

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Gridelli, Cesare,

Han, Ji-Youn,

Haney, Jeff,

Tiseo, Marcello,

Camidge, D. Ross,

Chang, Gee-Chen,

Yang, James Chih-Hsin,

Morabito, Alessandro,

Lee, Ki Hyeong,

Kim, Hye Ryun,

Bearz, Alessandra,

Kim, Dong-Wan,

Kerstein, David,

Garcia Campelo, Rosario,

Ghosh, Sharmistha,

Spira, Alexander,

Ahn, Myung-Ju,

Lee, Jong-Seok,

Griesinger, Frank,

Felip, Enriqueta,

Califano, Raffaele,

Gupta, Neeraj,

Hochmair, Maximilian J,

Gettinger, Scott N,

Delmonte, Angelo,

Li, Jacky Yu-Chung,

Popat, Sanjay

2018

Overview

In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity against central nervous system disease than crizotinib.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Anaplastic Lymphoma Kinase - analysis

/ Anaplastic Lymphoma Kinase - antagonists & inhibitors

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use